IraqTuberculosis profile
Population  2014 35 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.79 (0.016–3) 2.2 (0.04–8.6)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 24 (12–39) 67 (35–111)
Incidence  (includes HIV+TB) 15 (13–17) 43 (38–49)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.01 (0.01–0.01)
         
Case detection, all forms (%) 54 (48–62)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.1 (0.3–1.8) 20 (13–27)
MDR-TB cases among notified pulmonary
TB cases
51 (14–83) 110 (70–150)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 2 563   297
Pulmonary, clinically diagnosed 2 030   193
Extrapulmonary 3 069   116
       
Total new and relapse 8 268    
Previously treated, excluding relapses 73    
Total cases notified 8 341    
Among 8 268 new and relapse cases:
585 (7%) cases aged under 15 years; male:female ratio: 0.9
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 986 (38%) 250 (37%) 1 234
Laboratory-confirmed RR-/MDR-TB cases     196
Patients started on MDR-TB treatment ***     58
TB/HIV 2014 Number (%)
TB patients with known HIV status 3 925 (47)
HIV-positive TB patients 0 (0)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0  
HIV-positive TB patients on antiretroviral therapy (ART) 0  
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (88) 8 554
Previously treated cases, excluding relapse, registered in 2013 (79) 329
HIV-positive TB cases, all types, registered in 2013   0
RR-/MDR-TB cases started on second-line treatment in 2012 (47) 66
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 0.8
Culture (per 5 million population) 1.4
Drug susceptibility testing (per 5 million population) 0.1
Sites performing Xpert MTB/RIF 11
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 27
% Funded domestically 80%
% Funded internationally 20%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-02-13 Data: www.who.int/tb/data